Abstract
Previous studies have discovered disparity in death rates associated with SARS-CoV-2 infection in the United States during the initial stages of the pandemic. Specifically, the death rates were higher in the population in poverty and communities of color across the United States. In the current study, we perform the secondary analysis of death rates due to COVID-19 data, obtained from the Center for Disease Control and Prevention (CDC). Results indicate that in the first phase of the pandemic (February 1 to August 1, 2020), counties with higher percentage of White, Native Hawaiian and other Pacific Islanders, and two or more races populations were found to have lower per-capita COVID-19 death rate. Whereas counties with population having higher percentage of females, Black or African American people, and persons in poverty had higher death rates. Analysis of the death rates from August 1 to September 10, 2020, indicate that disparity continues with counties having higher population of Black or African American people and female having higher death rates. Poverty is not a significant variable in determining the death rates due to COVID-19. Based on the current data and lack of detailed molecular mechanism of the disease, we suggest that more resources must be diverted to counties with higher percentages of Black or African American and female populations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
See references.